anti-thymocyte globulin

Locations: 🇺🇸
University of Colorado Denver, Aurora, Colorado, United States
🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
🇺🇸
Buffalo General Hospital, Buffalo, New York, United States

and more 9 locations

Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Phase 2

Completed

Conditions: Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Childhood Acute Megakaryocytic Leukemia (M7)
Childhood Acute Monocytic Leukemia (M5b)
Childhood Myelodysplastic Syndromes
Recurrent Childhood Large Cell Lymphoma
Recurrent Mantle Cell Lymphoma
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome

Interventions: Procedure: double-unit umbilical cord blood transplantation
Other: cytogenetic analysis
Procedure: bone marrow aspiration
Other: fluorescence in situ hybridization
Drug: busulfan
Drug: cyclophosphamide
Drug: anti-thymocyte globulin
Drug: methylprednisolone
Drug: cyclosporine
Drug: mycophenolate mofetil
Other: flow cytometry
Procedure: allogeneic hematopoietic stem cell transplantation

First Posted Date: 2010-03-26

Last Posted Date: 2019-01-23

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 14

Registration Number: NCT01093586

Locations: 🇺🇸
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer

Phase 2

Terminated

Conditions: Adult Acute Lymphoblastic Leukemia in Remission
Adult Acute Myeloid Leukemia in Remission
Contiguous Stage II Mantle Cell Lymphoma
Adult Nasal Type Extranodal NK/T-cell Lymphoma
Blastic Phase Chronic Myelogenous Leukemia
Contiguous Stage II Grade 1 Follicular Lymphoma
Contiguous Stage II Grade 3 Follicular Lymphoma
Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma
Noncontiguous Stage II Adult Lymphoblastic Lymphoma
Noncontiguous Stage II Mantle Cell Lymphoma

Interventions: Drug: rituximab
Drug: mycophenolate mofetil
Drug: tacrolimus
Drug: anti-thymocyte globulin
Procedure: allogeneic hematopoietic stem cell transplantation
Other: laboratory biomarker analysis
Biological: graft versus host disease prophylaxis/therapy
Drug: cyclophosphamide
Drug: fludarabine phosphate
Drug: busulfan
Radiation: total-body irradiation
Biological: graft-versus-tumor induction therapy
Biological: immunosuppressive therapy

First Posted Date: 2010-01-08

Last Posted Date: 2023-09-06

Lead Sponsor: University of Nebraska

Target Recruit Count: 20

Registration Number: NCT01044745

Locations: 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States

Biochemical Correction of Severe EB by Allo HSCT and "Off-the-shelf" MSCs

Phase 1

Completed

Conditions: Epidermolysis Bullosa

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Myeloablative Busulfan
Drug: Anti-thymocyte globulin
Procedure: Mesenchymal stem cell transplantation
Procedure: Bone marrow or umbilical cord blood (UCG) stem cell transplantation
Radiation: Total body irradiation

First Posted Date: 2009-12-16

Last Posted Date: 2024-04-03

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 32

Registration Number: NCT01033552

Locations: 🇺🇸
University of Minnesota Masonic Cancer Center and Medical Center, Minneapolis, Minnesota, United States

Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia

Phase 1

Completed

Conditions: Juvenile Myelomonocytic Leukemia
Acute Myelogenous Leukemia
Myelodysplastic Syndrome

Interventions: Drug: Anti-Thymocyte Globulin
Drug: Fludarabine
Drug: Isotretinoin
Drug: Busulfan
Drug: GVHD Prophylaxis
Drug: Gemtuzumab Ozogamicin

First Posted Date: 2009-11-25

Last Posted Date: 2021-08-06

Lead Sponsor: Columbia University

Target Recruit Count: 18

Registration Number: NCT01020539

Locations: 🇺🇸
Columbia University Medical Center, New York, New York, United States

Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma

Phase 1

Withdrawn

Conditions: Multiple Myeloma
Refractory Multiple Myeloma

Interventions: Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Procedure: allogeneic bone marrow transplantation
Drug: bortezomib
Drug: melphalan
Drug: anti-thymocyte globulin
Drug: sirolimus
Drug: tacrolimus
Radiation: total-body irradiation

First Posted Date: 2009-10-14

Last Posted Date: 2023-01-05

Lead Sponsor: Mayo Clinic

Registration Number: NCT00995059

Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma

Phase 2

Completed

Conditions: Lymphoma, T-Cell, Cutaneous
Cutaneous T-cell Lymphoma
Mycoses
Sezary Syndrome
Bone Marrow Transplant Failure
Lymphoma, Non-Hodgkin

Interventions: Drug: anti-thymocyte globulin
Drug: cyclosporine
Radiation: Lymphoid radiation

First Posted Date: 2009-05-11

Last Posted Date: 2023-05-11

Lead Sponsor: Stanford University

Target Recruit Count: 38

Registration Number: NCT00896493

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States

Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma

Phase 2

Active, not recruiting

Conditions: Lymphoma, Non-Hodgkin

Interventions: Procedure: Stem cell infusion
Procedure: TLI
Drug: Anti-thymocyte globulin
Drug: Solumedrol
Drug: Tacrolimus
Drug: Mycophenolate mofetil

First Posted Date: 2009-04-17

Last Posted Date: 2025-01-28

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 18

Registration Number: NCT00882895

Locations: 🇺🇸
Washington University, Saint Louis, Missouri, United States

Autologous and Allogeneic Transplant for Relapsed Lymphoma

Phase 1

Completed

Conditions: Hodgkins Disease
Non-Hodgkin's Lymphoma

Interventions: Drug: Fludarabine
Drug: Busulfan
Drug: Anti-Thymocyte Globulin

First Posted Date: 2008-12-04

Last Posted Date: 2019-03-27

Lead Sponsor: Columbia University

Target Recruit Count: 30

Registration Number: NCT00802113

Locations: 🇺🇸
Children's Memorial Hospital in Chicago, Chicago, Illinois, United States
🇺🇸
Columbia University Medical Center, New York, New York, United States
🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States

and more 3 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy